Another TIGIT trial fails as BeiGene scraps Phase 3 drugnews2025-04-03T14:48:27+00:00April 3rd, 2025|Endpoints News|
Novartis’ Chinook-originated kidney disease drug gets accelerated approvalnews2025-04-03T11:36:16+00:00April 3rd, 2025|Endpoints News|
Sarepta, Roche pause Elevidys trials in Europe following patient deathnews2025-04-03T11:11:47+00:00April 3rd, 2025|Endpoints News|
Edgewise’s heart drug shows promise in Phase 2 trialnews2025-04-02T11:20:54+00:00April 2nd, 2025|Endpoints News|
Axsome reports Phase 3 depression fail for Sunosinews2025-04-01T15:00:08+00:00April 1st, 2025|Endpoints News|
Compass Therapeutics’ cancer trial succeeds, needs more datanews2025-04-01T14:55:03+00:00April 1st, 2025|Endpoints News|
Gubra’s AbbVie-partnered amylin looks competitive with Zealand’s in early trialnews2025-04-01T14:39:31+00:00April 1st, 2025|Endpoints News|
Big ambitions at Merck and AstraZeneca — along with a few giant pitfalls — reshape top ranks of the R&D 15news2025-04-01T11:00:51+00:00April 1st, 2025|Endpoints News|
RNA editing startup AIRNA raises $155M for liver and lung disease therapynews2025-04-01T11:00:16+00:00April 1st, 2025|Endpoints News|
Lilly claims Phase 2 win for siRNA approach to mixed dyslipidemianews2025-04-01T10:52:03+00:00April 1st, 2025|Endpoints News|
